Actively Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Led by Daiichi Sankyo · Updated on 2026-04-20
540
Participants Needed
33
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
CONDITIONS
Official Title
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated the main Informed Consent Form (ICF)
- Left ventricular ejection fraction 50% or higher within 28 days before enrollment
- Adequate organ function
- Measurable disease based on RECIST V1.1
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Histologically or cytologically confirmed locally advanced, metastatic, or unresectable solid malignant tumors (Part 1)
- Histologically or cytologically confirmed locally advanced, metastatic, or unresectable cancer with documented disease progression after recent anticancer therapy (Part 2)
- Ability to provide baseline tumor samples through fresh biopsy or recent archived tissue samples obtained within 6 months before signing ICF (Part 2)
You will not qualify if you...
- Prior treatment targeting mucin 1 (MUC1) or TA-MUC1
- Spinal cord compression or active central nervous system metastases
- Multiple primary malignancies except certain treated skin or in situ cancers with no disease evidence for 3 or more years
- History or current noninfectious interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis not ruled out by imaging
- Active or uncontrolled HIV infection
- Active or uncontrolled hepatitis B or C infection
- Cerebrovascular accident, transient ischemic attack, or arterial thromboembolic event within past 6 months
- Active, known, or suspected autoimmune disease
- Current participation in other therapeutic investigational procedures except for Long Term Follow-Up without investigational treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 33 locations
1
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
2
Oregon Health & Science University
Portland, Oregon, United States, 97239
Actively Recruiting
3
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
4
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
6
The Medical College of Wisconsin, INC
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
7
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
8
McGill University Health Center
Montreal, Canada, H4A 3J1
Not Yet Recruiting
9
Princess Margaret Cancer Center
Toronto, Canada, M5G2M9
Actively Recruiting
10
Beijing Cancer Hospital
Beijing, China, 100142
Not Yet Recruiting
11
Shandong Cancer Hospital
Jinan, China, 250117
Actively Recruiting
12
The Second Peoples Hospital of Neijiang
Neijiang, China, 641000
Actively Recruiting
13
Shanghai East Hospital
Shanghai, China, 200120
Actively Recruiting
14
Centre Léon Bérard
Lyon, France, 69008
Actively Recruiting
15
Assistance Publique- de Marseille
Marseille, France, 13005
Actively Recruiting
16
Chu Strasbourg
Strasbourg, France, 67091
Actively Recruiting
17
Institut Claudius Regaud
Toulouse, France, 31059
Actively Recruiting
18
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
19
National Cancer Center Hospital
Chūōku, Japan, 104-0045
Actively Recruiting
20
Kansai Medical University Hospital
Hirakata-shi, Japan, 573-1191
Actively Recruiting
21
National Cancer Center Hospital East
Kashiwa, Japan, 277-8577
Actively Recruiting
22
Cancer Institute Hospital of Jfcr
Kōtoku, Japan, 135-8550
Actively Recruiting
23
Kindai University Hospital
Ōsaka-sayama, Japan, 589-8511
Actively Recruiting
24
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
25
Severance Hospital, Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
26
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
27
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
28
Hospital Universitari Vall D'Hebron
Barcelona, Spain, 8035
Actively Recruiting
29
Hospital Universitario Ramon Y Cajal
Madrid, Spain, 28034
Actively Recruiting
30
Hospital Universitario La Paz
Madrid, Spain, 28046
Actively Recruiting
31
Hospital Regional Universitario de Malaga
Málaga, Spain, 29010
Actively Recruiting
32
Next Madrid
Pozuelo de Alarcón, Spain, 28223
Actively Recruiting
33
Hospital Universitario Virgen Macarena
Seville, Spain, 41009
Actively Recruiting
Research Team
(
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
(
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here